Michael Kauffman - 21 Aug 2024 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Role
Director
Signature
/s/ Nick Harvey, Attorney-in-Fact
Issuer symbol
ACET
Transactions as of
21 Aug 2024
Net transactions value
$0
Form type
4
Filing time
23 Aug 2024, 16:05:45 UTC
Previous filing
21 Jun 2024
Next filing
27 May 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACET Stock Option (Right to Buy) Disposed to Issuer $0 -37,000 -100% $0.000000 0 21 Aug 2024 Common Stock 37,000 $2.14 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Award $0 +37,000 $0.000000 37,000 21 Aug 2024 Common Stock 37,000 $9.39 Direct F1, F2
transaction ACET Stock Option (Right to Buy) Disposed to Issuer $0 -18,500 -100% $0.000000 0 21 Aug 2024 Common Stock 18,500 $2.14 Direct F1, F3
transaction ACET Stock Option (Right to Buy) Award $0 +18,500 $0.000000 18,500 21 Aug 2024 Common Stock 18,500 $11.49 Direct F1, F3
transaction ACET Stock Option (Right to Buy) Disposed to Issuer $0 -26,400 -100% $0.000000 0 21 Aug 2024 Common Stock 26,400 $2.14 Direct F1, F3
transaction ACET Stock Option (Right to Buy) Award $0 +26,400 $0.000000 26,400 21 Aug 2024 Common Stock 26,400 $5.20 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Michael Kauffman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2 The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on November 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
F3 The shares subject to this option are fully vested and exercisable as of the date hereof.